Back to School: How biopharma can reboot drug development. Access exclusive analysis here

July 14 Quick Takes: Cytokinetics accesses cash via royalty, licensing deals; plus Junshi-Revitope and Sanofi-MD Anderson

Cytokinetics in deals with Chinese biotech, investor
Cytokinetics Inc. (NASDAQ:CYTK) said it could receive $250 million in committed capital and $200 million in milestones via a series of deals

Read the full 289 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE